108

CLINICAL RELEVANCE OF ADDITION OF CONVENTIONAL TREATMENT TO CONCURRENT CHEMORADIOTHERAPY IN PATIENTS WITH FIGO STAGE III-IV CERVICAL CANCER

H Kurosu*, Y Todo, Y Suzuki, R Yamada, K Minowa, S Minobe, H Kato. *National Hospital Organization, Hokkaido Cancer Center, Division of Gynecologic Oncology, Sapporo, Japan*

10.1136/ijgc-2021-ESGO.6

Introduction/Background* Concurrent chemoradiotherapy (CCRT) has limited therapeutic efficacy for stage III-IV cervical cancer. We aimed to identify a subgroup of patients with stage III-IV cervical cancer who benefit from CCRT with additional treatment.

Methodology We retrospectively reviewed 120 patients with stage III-IV cervical cancer who were treated with CCRT from 2002 to 2018. We compared overall survival between patients treated with CCRT alone and those who received CCRT with additional conventional treatments (systemic chemotherapy before and/or after CCRT and/or extended-field radiation). Prognostic factors were statistically analyzed.

Result(s)* Overall, 44 (36.7%) and 21 (17.5%) patients were radiologically diagnosed with pelvic and para-aortic lymph node enlargement, respectively. The median tumor diameter was 5.7 cm. Sixty-nine (57.5%) patients received no additional treatment, and 51 (42.5%) received additional treatment. Cox regression analysis identified the following prognostic factors: histological non-squamous cell carcinoma (hazard ratio [HR], 3.9; 95% confidence interval [CI], 1.8–8.2), tumor diameter of ≥ 6 cm (HR, 2.1; 95% CI, 1.2–3.7), radiological pelvic lymph node enlargement (HR, 2.1; 95% CI, 1.1–4.0), and radiological para-aortic lymph node enlargement (HR, 2.1; 95% CI, 1.1–4.1). Even in the lowest risk group (no risk factors), the 5-year overall survival rate was lower in the additional treatment group than in the CCRT alone group (78.7% vs. 80.9%, respectively; log-rank test, $P = 0.79$).

Conclusion* Addition of conventional treatments to CCRT might not improve survival in patients with advanced cervical cancer. Novel treatment strategies including immune checkpoint inhibitors should be considered for such patients.

114

LOWER-LIMB LYMPHEDEMA AFTER SENTINEL LYMPH NODE BIOPSY IN CERVICAL CANCER PATIENTS

¹R Poncová*, ¹R Kocián, ²S Marnitz, ³J Jarkovský, ⁴J Klát, ⁵R Pilka, ⁶A Torné, ⁷I Zapardiel, ⁸A Petiz, ⁹L Lay, ¹⁰B Sehnal, ¹¹J Ponce, ¹²M Felsinger, ¹³O Arencibia-Sánchez, ¹⁴P Kaščák, ¹⁵K Zalewski, ²C Köhler, ¹F Frühauf, ¹M Borčinová, ¹D Cibula. ¹Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic; ²Department of Special Operative and Oncologic Gynaecology, Asklepios-Clinic Hamburg, Hamburg, Germany; ³Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic; ⁴Department of Obstetrics and Gynecology, University Hospital Ostrava, Ostrava Poruba, Czech Republic (Central and Eastern European Gynecologic Oncology Group, CEEGOG); ⁵Department of Obstetrics and Gynecology, Faculty of Medicine and Dentistry, Palacky University, University Hospital Olomouc, Olomouc, Czech Republic (Central and Eastern European Gynecologic Oncology Group, CEEGOG); ⁶Unit of Gynecological Oncology, Institute Clinic of Gynaecology, Obstetrics, and Neonatology, Hospital Clinic-Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain; ⁷Gynecologic Oncology Unit, La Paz University Hospital, Madrid, Spain; ⁸Instituto Português de Oncologia do Porto, Portugal; ⁹Department of Gynaecology, Institute of Oncology Angel H Roffo University of Buenos Aires, Buenos Aires, Argentina; ¹⁰Department of Obstetrics and Gynecology, University Hospital Bulovka, First Faculty of Medicine, Charles University, Prague, Czech Republic (Central and Eastern European Gynecologic Oncology Group, CEEGOG); ¹¹Department of Gynecology, University Hospital of Bellvitge, Biomedical Research Institute of Bellvitge, (IDIBELL), University of Barcelona, Barcelona, Spain; ¹²Department of Gynecology and Obstetrics, Faculty of Medicine, Masaryk University, Brno, Czech Republic (Central and Eastern European Gynecologic Oncology Group, CEEGOG); ¹³University Hospital of the Canary Islands, Las Palmas de Gran Canaria, Spain; ¹⁴Department of Obstetrics and Gynecology, Faculty Hospital Trencin, Trencin, Slovakia (Central and Eastern European Gynecologic Oncology Group, CEEGOG); ¹⁵Department of Gynecologic Oncology, Holycross Cancer Center, Kielce, Poland (Central and Eastern European Gynecologic Oncology Group, CEEGOG)

10.1136/ijgc-2021-ESGO.7

Introduction/Background* Lower-limb lymphedema (LLL) is a well-recognized adverse outcome of the surgical management of cervical cancer. Recently, sentinel lymph node (SLN) biopsy has emerged as an alternative procedure to systematic pelvic lymphadenectomy (PLND) aiming to decrease the risk of complications, especially LLL development. Our study represents the first prospective analysis of LLL incidence in cervical cancer patients after a uterine procedure with SLN biopsy, without systematic PLND.

Abstract 114 Figure 1